SCHEMBL4154078

SCHEMBL4154078

Nc1ccnc2ccc(-c3nccs3)cc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 2/20 0.50
LOXL2 Q9Y4K0 1/20 0.46
LRRK2 Q5S007 1/20 0.44
NCF1 P14598 1/20 0.43
PDPK1 O15530 1/20 0.43
HDAC2 Q92769 2/20 0.43
HSP90AA1 P07900 2/20 0.41
TGFBR1 P36897 1/20 0.41
TLR8 Q9NR97 1/20 0.40
TLR7 Q9NYK1 1/20 0.40
PIK3CD O00329 1/20 0.40
ABL1 P00519 1/20 0.40
EGFR P00533 1/20 0.40
HCK P08631 1/20 0.40
SRC P12931 1/20 0.40
KDR P35968 1/20 0.40
PIK3CA P42336 1/20 0.40
PIK3CB P42338 1/20 0.40
MTOR P42345 1/20 0.40
PIK3CG P48736 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1068648 0.76 LOXL2 (0.55) LOXL2LRRK2PDPK1HDAC2HSP90AA1
SCHEMBL4151090 0.73 MAP4K4 (0.60) NR4A2NCF1PIK3CDABL1EGFR
SCHEMBL29061683 0.73 MAP4K4 (0.60) NR4A2NCF1PIK3CDABL1EGFR
SCHEMBL5758549 0.73 NR4A2 (0.56) NR4A2NCF1HSP90AA1PIK3CDABL1
SCHEMBL2489977 0.73 PDPK1 (0.52) LOXL2PDPK1HDAC2HSP90AA1TLR8
SCHEMBL1830952 0.72 ALDH1A1 (0.53) LOXL2LRRK2PDPK1HDAC2HSP90AA1
SCHEMBL3247666 0.72 LOXL2 (0.50) LOXL2PDPK1HDAC2HSP90AA1TLR8
SCHEMBL10013456 0.71 PDPK1 (0.60) LOXL2LRRK2PDPK1HDAC2TLR8
SCHEMBL722198 0.71 PDPK1 (0.77) LOXL2PDPK1HDAC2HSP90AA1ABL1
SCHEMBL1867311 0.71 LCK (0.50) LOXL2LRRK2PDPK1HDAC2HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090069338-A1 Method for predicting skin sensitizing activity of compounds DICKSON JR JOHN K 2009-03-12 US disclosed
US-7452887-B2 Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof AMPHORA DISCOVERY CORPORATION (US) 2008-11-18 US disclosed
US-20060009460-A1 Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof AGRIUS GROUP, LLC. 2006-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069338-A1 Method for predicting skin sensitizing activity of compounds ATP5ME, ABCG2, ATP5MG NR4A2 1882/4885LOXL2 2465/4885LRRK2 4775/4885
US-20060009460-A1 Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof ATP5ME, ATP5MG, ATP5MK NR4A2 3517/4885LOXL2 4045/4885LRRK2 4070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.